A Single-Arm, Open-Label, Multicenter Feasibility Trial of Bevacizumab Given in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Locally Advanced Unresectable Non-Squamous, Non-Small Cell Lung Cancer.

Trial Profile

A Single-Arm, Open-Label, Multicenter Feasibility Trial of Bevacizumab Given in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Locally Advanced Unresectable Non-Squamous, Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 06 Dec 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 17 Aug 2010 Planned end date changed from 1 Oct 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 27 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top